Loading briefing details...
News Abstract
By: PointLine Media Research & Editorial Team
Topic:Business,Education,Industry,Lifestyle,Technology
November 12, 2026
Resilient Performance Group has identified a significant oversight in international pharmaceutical licensing known as the Landing Gap. This term describes the financial and operational exposure that occurs when drugs developed in one regulatory environment are transitioned to another, particularly the U.S. market.
Founder Brian Baldari notes that while companies are aggressively acquiring early-stage assets from abroad, they often fail to account for the costs of adapting these products to domestic payer systems and regulatory labels. This lack of rigorous due diligence leaves potential commercial hurdles unpriced during the initial deal phase.
The firm has formalized this advisory work into a dedicated practice, Cross-Border Commercial Readiness. This initiative provides strategic oversight for organizations that lack standing commercial teams, focusing on aligning international development programs with U.S. market access requirements.
The pharmaceutical industry is seeing a surge in cross-border licensing, with deal values in regions like China reaching $137.7 billion by 2025. Companies are increasingly acquiring assets at the preclinical or Phase 1 stage, creating a race to secure potential treatments before they are fully understood by domestic regulators.
This trend highlights a disconnect between scientific potential and commercial viability. As firms prioritize speed and volume in their acquisition strategies, they often neglect the complexities of navigating diverse reimbursement landscapes, which can ultimately threaten the long-term success of imported drug candidates.